The FDA has expanded the indications for abemaciclib (Verzenio, Eli Lilly) in early and metastatic breast cancer, according to a press release from Eli Lilly. Abemaciclib no longer requires results from a biomarker test to treat certain patients with early breast cancer (EBC), and abemaciclib can now be used to treat patients with metastatic breast cancer (MBC), regardless of menopausal status.
The FDA approved an expanded indication for abemaciclib in combination with endocrine therapy (ET),
MARCH 31, 2023